Capivasertib Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 160 mg
Reference Brands: Truqap (USA)
Category:
Oncology Cancer Care
Capivasertib is available in Tablets
and strengths such as 160 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Capivasertib is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Capivasertib can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Capivasertib, also known by the brand name Truqap, is an oral targeted anticancer therapy used in combination with fulvestrant for the treatment of adults with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer. It is specifically indicated for patients whose disease has progressed during or after prior hormone therapy and who have genetic alterations in the PIK3CA, AKT1, or PTEN genes.
Capivasertib works by selectively inhibiting AKT, a key protein involved in cell signaling pathways that regulate cancer cell growth, survival, and metabolism. By blocking AKT activity, capivasertib disrupts these pathways, helping to slow tumor growth and potentially induce cancer cell death. It belongs to the class of kinase inhibitors and represents an important advancement in precision oncology.
The drug is administered orally under specialist supervision and is being actively studied for use in other cancer types where AKT pathway abnormalities play a role. Capivasertib’s targeted mechanism allows for a more personalized treatment approach, offering improved outcomes for patients with specific molecular profiles while supporting long-term disease control in advanced breast cancer.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing